Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOONRAY-01
jRCT2041240103Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of LY3962673 in pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with one or more treatment-emergent adverse events and serious adverse events related to study drug administration, Number of participants with dose-limiting toxicities and 6 more. Started Oct 2024; status: recruiting.
02
Drugs
LY3962673
03
Conditions
pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2041240103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240103.